Chargement en cours...
Ubrogepant in the Acute Management of Migraine: A Narrative Review
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. The ACHIEVE I and ACHIEVE II Phase III clinical trials showed that ubrogepant was s...
Enregistré dans:
| Publié dans: | J Pain Res |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8088294/ https://ncbi.nlm.nih.gov/pubmed/33948091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JPR.S244249 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|